Nuvectis Pharma Inc
Research Nuvectis Pharma Inc (NVCT) on Bullrun: market cap USD 691.13M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNVCT
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 691.13M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 7.02M
- Free cash flow-USD 4.53M
Valuation Snapshot
latest market cap is USD 691.13M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 26.44M | -USD 16.01M | n/a | -1.32 | USD 31.63M | n/a | USD 18.41M |
| FY2024 | USD 0 | -USD 19.00M | -USD 12.25M | n/a | -1.11 | USD 18.53M | n/a | USD 9.71M |
| FY2023 | n/a | -USD 22.26M | n/a | n/a | -1.43 | USD 19.13M | n/a | USD 12.20M |
| FY2022 | n/a | -USD 19.09M | n/a | n/a | -1.51 | USD 19.99M | n/a | USD 14.22M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 691.13M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 193.86M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 105.47M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 144.50M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 109.82M | n/a | n/a | n/a |
About Nuvectis Pharma Inc
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Nuvectis Pharma Inc's market cap?
Nuvectis Pharma Inc's market capitalization is USD 691.13M.
What does Nuvectis Pharma Inc do?
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.